Quality of Life Related to Different Treatment Protocols for Post-thyroidectomy Hypoparathyroidism
Comparing the Quality of Life Associated With Empiric Calcium Repletion and Parathormone (PTH) Based Calcium Repletion for Post Thyroidectomy Hypoparathyroidism
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Enrolled patients will be randomized in two treatment groups. In group 1, all patients will receive calcium carbonate and calcitriol in the post-operative period, with standardized weaning. In group 2, patients will be prescribed calcium carbonate and calcitriol only if their post-operative PTH dosage is 25% or less of the pre-operative dosage, or if post-operative PTH is inferior to 15.
The Short-Form 36 (SF-36) questionnaire (French canadian version) will be used to assess quality of life pre-operatively and at post-op week 1 and 4. Symptoms of hypocalcemia and adverse effects of calcium carbonate and calcitriol will be monitored at week 1 and 4.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jean-Philippe Vezina, MD, FRCSC
- Phone Number: 418-649-0252
- Email: jean-philippe.vezina@fmed.ulaval.ca
Study Locations
-
-
Quebec
-
Québec, Quebec, Canada, G1J1Z4
- Recruiting
- Chu De Quebec
-
Contact:
- Jean-Philippe Vezina, MD
- Phone Number: 418-649-0252
- Email: jean-philippe.vezina@fmed.ulaval.ca
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Total thyroidectomy or completion hemithyroidectomy
Exclusion Criteria:
- Need for neck dissection
- Unable to fill in questionnaires (intellectual deficit, severe psychiatric disorder, illiterate, does not speak French or English)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Empiric calcium and calcitriol repletion group
All patients in this group will receive post-operative calcium carbonate and calcitriol.
|
Empiric calcium carbonate and calcitriol repletion
|
|
Experimental: PTH based repletion group
Patients in this group will be prescribed calcium carbonate and calcitriol based on their post-operative PTH.
|
PTH based treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline quality of life at 1 and 4 weeks
Time Frame: Pre-op, 1 week post-op and 4 weeks post-op
|
Short Form 36 (SF-36) questionnaire
|
Pre-op, 1 week post-op and 4 weeks post-op
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Occurence and change in pharmacologic adverse effects of calcium carbonate and calcitriol
Time Frame: 1 week post-op, 4 weeks post-op
|
A questionnaire about the adverse effects of calcium carbonate and calcitriol will be completed at post-op week 1 and 4
|
1 week post-op, 4 weeks post-op
|
|
Occurence and change in symptoms of hypocalcemia
Time Frame: 1 week post-op, 4 weeks post-op
|
A questionnaire about symptoms of hypocalcemia will be completed at post-op week 1 and 4.
|
1 week post-op, 4 weeks post-op
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Parathyroid Diseases
- Hypoparathyroidism
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Gastrointestinal Agents
- Micronutrients
- Membrane Transport Modulators
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vasoconstrictor Agents
- Antacids
- Calcium Channel Agonists
- Calcium
- Calcium, Dietary
- Calcium Carbonate
- Calcitriol
Other Study ID Numbers
Other Study ID Numbers
- 2018-3422
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Quality of Life
-
NCT07378215RecruitingQuality of Life | Postoperative Quality of Recovery | Health-Related Quality-of-Life
-
NCT04239183UnknownQuality of Life of Colostomized Patient
-
NCT02901639UnknownImproving Quality of Life
-
NCT04761367CompletedImprove Quality of Life
-
NCT05722249CompletedProfessional Quality of Life
-
NCT06014671CompletedBreif Description: Patients' Quality of Life of
-
NCT06262334RecruitingHealth Related Quality of Life
-
NCT01155076CompletedHealth-related Quality of Life
-
NCT01784497CompletedHealth Related Quality of Life
Clinical Trials on Empiric use of Calcium Carbonate and Calcitriol
-
NCT05252884CompletedGoiter | Hyperthyroidism | Thyroid Cancer | Thyroiditis
-
NCT03068533Unknown
-
NCT01994733CompletedEnd-stage Renal Disease
-
NCT00298545CompletedAdenocarcinoma | Colorectal Polyps | Colorectal Adenoma
-
NCT01317940CompletedVitamin D Deficiency | Precursor Cell Lymphoblastic Leukemia-Lymphoma
-
NCT01748396CompletedChronic Kidney Disease Stage 3
-
NCT01514851Completed